Last reviewed · How we verify
full-dose olanzapine
full-dose olanzapine is a Atypical antipsychotic Small molecule drug developed by Kaohsiung Kai-Suan Psychiatric Hospital. It is currently FDA-approved for Schizophrenia, Bipolar I disorder (acute mania and maintenance), Treatment-resistant depression (adjunctive use). Also known as: polypharmacy.
Olanzapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain.
Full-dose olanzapine is used to treat schizophrenia. It works as a serotonin 2a (5-HT2a) receptor antagonist, a type of small molecule that blocks the action of serotonin at this receptor.
At a glance
| Generic name | full-dose olanzapine |
|---|---|
| Also known as | polypharmacy |
| Sponsor | Kaohsiung Kai-Suan Psychiatric Hospital |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2 receptor, Serotonin 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Olanzapine antagonizes dopamine D2 receptors in the mesolimbic and mesocortical pathways, reducing psychotic symptoms, while also blocking serotonin 5-HT2A receptors which may enhance antipsychotic efficacy and reduce extrapyramidal side effects. It also has activity at multiple other receptors including muscarinic, histamine H1, and alpha-adrenergic receptors, contributing to its broader clinical effects.
Approved indications
- Schizophrenia
- Bipolar I disorder (acute mania and maintenance)
- Treatment-resistant depression (adjunctive use)
Common side effects
- Weight gain
- Sedation
- Metabolic syndrome / hyperglycemia
- Hyperlipidemia
- Akathisia
- Orthostatic hypotension
- Prolactin elevation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- full-dose olanzapine CI brief — competitive landscape report
- full-dose olanzapine updates RSS · CI watch RSS
- Kaohsiung Kai-Suan Psychiatric Hospital portfolio CI
Frequently asked questions about full-dose olanzapine
What is full-dose olanzapine?
How does full-dose olanzapine work?
What is full-dose olanzapine used for?
Who makes full-dose olanzapine?
Is full-dose olanzapine also known as anything else?
What drug class is full-dose olanzapine in?
What development phase is full-dose olanzapine in?
What are the side effects of full-dose olanzapine?
What does full-dose olanzapine target?
Related
- Drug class: All Atypical antipsychotic drugs
- Target: All drugs targeting Dopamine D2 receptor, Serotonin 5-HT2A receptor
- Manufacturer: Kaohsiung Kai-Suan Psychiatric Hospital — full pipeline
- Therapeutic area: All drugs in Psychiatry
- Indication: Drugs for Schizophrenia
- Indication: Drugs for Bipolar I disorder (acute mania and maintenance)
- Indication: Drugs for Treatment-resistant depression (adjunctive use)
- Also known as: polypharmacy
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing